282 related articles for article (PubMed ID: 33995674)
1. Targeted inhibition of SIRT6 via engineered exosomes impairs tumorigenesis and metastasis in prostate cancer.
Han Q; Xie QR; Li F; Cheng Y; Wu T; Zhang Y; Lu X; Wong AST; Sha J; Xia W
Theranostics; 2021; 11(13):6526-6541. PubMed ID: 33995674
[TBL] [Abstract][Full Text] [Related]
2. MDL-800, an allosteric activator of SIRT6, suppresses proliferation and enhances EGFR-TKIs therapy in non-small cell lung cancer.
Shang JL; Ning SB; Chen YY; Chen TX; Zhang J
Acta Pharmacol Sin; 2021 Jan; 42(1):120-131. PubMed ID: 32541922
[TBL] [Abstract][Full Text] [Related]
3. Silencing of EphA2 inhibits invasion of human gastric cancer SGC-7901 cells in vitro and in vivo.
Yuan W; Chen Z; Chen Z; Wu S; Guo J; Ge J; Yang P; Huang J
Neoplasma; 2012; 59(1):105-13. PubMed ID: 22103904
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
5. Adeno-associated virus-delivered short hairpin-structured RNA for androgen receptor gene silencing induces tumor eradication of prostate cancer xenografts in nude mice: a preclinical study.
Sun A; Tang J; Terranova PF; Zhang X; Thrasher JB; Li B
Int J Cancer; 2010 Feb; 126(3):764-74. PubMed ID: 19642108
[TBL] [Abstract][Full Text] [Related]
6. Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis.
Zhang Y; Zhao J; Ding M; Su Y; Cui D; Jiang C; Zhao S; Jia G; Wang X; Ruan Y; Jing Y; Xia S; Han B
J Exp Clin Cancer Res; 2020 Dec; 39(1):282. PubMed ID: 33317606
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer.
Shi SJ; Wang LJ; Han DH; Wu JH; Jiao D; Zhang KL; Chen JW; Li Y; Yang F; Zhang JL; Zheng GX; Yang AG; Zhao AZ; Qin WJ; Wen WH
Theranostics; 2019; 9(5):1247-1263. PubMed ID: 30867828
[No Abstract] [Full Text] [Related]
8. Quercetin inhibited the proliferation and invasion of hepatoblastoma cells through facilitating SIRT6-medicated FZD4 silence.
Liu T; Li Z; Tian F
Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S96-S107. PubMed ID: 34219513
[TBL] [Abstract][Full Text] [Related]
9. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
10. siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer.
Yamamoto Y; Lin PJ; Beraldi E; Zhang F; Kawai Y; Leong J; Katsumi H; Fazli L; Fraser R; Cullis PR; Gleave M
Clin Cancer Res; 2015 Nov; 21(21):4845-55. PubMed ID: 26106075
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of SIRT6 in prostate cancer reduces cell viability and increases sensitivity to chemotherapeutics.
Liu Y; Xie QR; Wang B; Shao J; Zhang T; Liu T; Huang G; Xia W
Protein Cell; 2013 Sep; 4(9):702-10. PubMed ID: 23982738
[TBL] [Abstract][Full Text] [Related]
12. SIRT6 Overexpression Potentiates Apoptosis Evasion in Hepatocellular Carcinoma via BCL2-Associated X Protein-Dependent Apoptotic Pathway.
Ran LK; Chen Y; Zhang ZZ; Tao NN; Ren JH; Zhou L; Tang H; Chen X; Chen K; Li WY; Huang AL; Chen J
Clin Cancer Res; 2016 Jul; 22(13):3372-82. PubMed ID: 26861461
[TBL] [Abstract][Full Text] [Related]
13. Prostate carcinoma cell-derived exosomal MicroRNA-26a modulates the metastasis and tumor growth of prostate carcinoma.
Wang X; Wang X; Zhu Z; Li W; Yu G; Jia Z; Wang X
Biomed Pharmacother; 2019 Sep; 117():109109. PubMed ID: 31229922
[TBL] [Abstract][Full Text] [Related]
14. In vivo targeting of ADAM9 gene expression using lentivirus-delivered shRNA suppresses prostate cancer growth by regulating REG4 dependent cell cycle progression.
Liu CM; Hsieh CL; He YC; Lo SJ; Liang JA; Hsieh TF; Josson S; Chung LW; Hung MC; Sung SY
PLoS One; 2013; 8(1):e53795. PubMed ID: 23342005
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule activating SIRT6 elicits therapeutic effects and synergistically promotes anti-tumor activity of vitamin D
Shang J; Zhu Z; Chen Y; Song J; Huang Y; Song K; Zhong J; Xu X; Wei J; Wang C; Cui L; Liu CY; Zhang J
Theranostics; 2020; 10(13):5845-5864. PubMed ID: 32483423
[TBL] [Abstract][Full Text] [Related]
16. RNA interference targeting PSCA suppresses primary tumor growth and metastasis formation of human prostate cancer xenografts in SCID mice.
Zhao Z; He J; Kang R; Zhao S; Liu L; Li F
Prostate; 2016 Feb; 76(2):184-98. PubMed ID: 26477693
[TBL] [Abstract][Full Text] [Related]
17. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
[TBL] [Abstract][Full Text] [Related]
18. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
[TBL] [Abstract][Full Text] [Related]
19. Effective targeting of RNA polymerase I in treatment-resistant prostate cancer.
Low JY; Sirajuddin P; Moubarek M; Agarwal S; Rege A; Guner G; Liu H; Yang Z; De Marzo AM; Bieberich C; Laiho M
Prostate; 2019 Dec; 79(16):1837-1851. PubMed ID: 31524299
[TBL] [Abstract][Full Text] [Related]
20. A novel RNA aptamer identifies plasma membrane ATP synthase beta subunit as an early marker and therapeutic target in aggressive cancer.
Speransky S; Serafini P; Caroli J; Bicciato S; Lippman ME; Bishopric NH
Breast Cancer Res Treat; 2019 Jul; 176(2):271-289. PubMed ID: 31006104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
